Jump to content

Estrapronicate/hydroxyprogesterone heptanoate/nandrolone undecanoate

Add links
From Wikipedia, the free encyclopedia
(Redirected from Trophobolene)
EPC/OHPH/NU
Combination of
EstrapronicateEstrogen
Hydroxyprogesterone heptanoateProgestogen
Nandrolone undecanoateAndrogen; Anabolic steroid
Clinical data
Trade namesTrophobolene, Trophoboline
Other namesEPC/OHPH/NU
Pregnancy
category
  • f
Routes of
administration		Intramuscular injection
Identifiers
CAS Number

Estrapronicate/hydroxyprogesterone heptanoate/nandrolone undecanoate (EPC/OHPH/NU), tentative brand name Trophobolene or Trophoboline, is an injectable combination medication of estrapronicate (EPC; estradiol nicotinate propionate), an estrogen, hydroxyprogesterone heptanoate (OHPH), a progestogen, and nandrolone undecanoate (NU), an androgen/anabolic steroid, which was never marketed.[1][2] It contained 1.3 mg EPC, 80 mg OHPH, and 50 mg NU in oil solution and was administered by intramuscular injection.[1][2][3] The medication was developed by Théramex in the mid-to-late 1960s.[4][1][2] It was studied for use for a variety of indications, including treatment of coronary insufficiency, growth deficiency, and osteoporosis, as well as hormonal disorders in gonadotropin deficiency.[1]

In contrast to other anabolic steroid-containing preparations, EPC/OHPH/NU reportedly had no masculinizing effects, and its estrogenic component likewise reportedly had no feminizing effects.[1] The nicotinic acid (niacin; vitamin B3) derived from estrapronicate was said to enhance the nutrient, relaxant, and antiadipose effects of the estrogenic component.[1]

The pharmacokinetics of nandrolone undecanoate in this combination preparation have been studied as well as compared to nandrolone alone (Dynabolon).[5]

See also

[edit]

References

[edit]
  1. ^ a b c d e f Polish Endocrinology. Państwowy Zakład Wydawnuictw Lekarskich (National Institute of Medical Publishing). 1969. p. 210.
  2. ^ a b c Vignon G, Pansu D (15 January 1967). "Le traitement de l'ostéoporose par le trophobolène" [The treatment of osteoporosis by trophobolene]. Rev Lyon Med (in French). 16 (1): 31–8. ISSN 0556-798X. PMID 5595570.
  3. ^ Action QA, ed. (21 June 2013). "Nandrolone". Testosterone Congeners—Advances in Research and Application: 2013 Edition: ScholarlyBrief. ScholarlyEditions. pp. 137–. ISBN 978-1-4816-9288-5. Table 1 Oil based long-acting intramuscular injections products [...] Trophobolene: Estrapronicate 1.3 mg [...] Nandrolone undecanoate 50 mg Hydroxyprogesterone heptanoate 80 mg.
  4. ^ Kleemann A, Engel JD (2001). Pharmaceutical substances: syntheses, patents, applications. Thieme. p. 1397. ISBN 978-3-13-558404-1.
  5. ^ Courtot D, Forichon J, Paris J (1983). "Pharmacokinetics of 19-Nortestosterone in Man". Chromatography in Biochemistry, Medicine, and Environmental Research, 1: Proceedings of the 1st International Symposium on Chromatography in Biochemistry, Medicine and Environmental Research, Venice, June 16–17, 1981. Analytical Chemistry Symposia Series. Vol. 13. Amsterdam/Oxford/New York: Elsevier. pp. 95–110.


Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://wiki.riteme.site/w/index.php?title=Estrapronicate/hydroxyprogesterone_heptanoate/nandrolone_undecanoate&oldid=1184596436"